Italia Grenga

2.0k total citations · 1 hit paper
43 papers, 1.6k citations indexed

About

Italia Grenga is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Italia Grenga has authored 43 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 23 papers in Immunology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Italia Grenga's work include Cancer Immunotherapy and Biomarkers (23 papers), Immunotherapy and Immune Responses (14 papers) and Immune Cell Function and Interaction (8 papers). Italia Grenga is often cited by papers focused on Cancer Immunotherapy and Biomarkers (23 papers), Immunotherapy and Immune Responses (14 papers) and Immune Cell Function and Interaction (8 papers). Italia Grenga collaborates with scholars based in United States, Italy and Germany. Italia Grenga's co-authors include Renee N. Donahue, Jeffrey Schlom, James L. Gulley, Christopher R. Heery, Ravi A. Madan, Lauren M. Lepone, Jennifer L. Marté, Lisa M. Cordes, Elizabeth Lamping and Benedetto Farsaci and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Cancer Research.

In The Last Decade

Italia Grenga

43 papers receiving 1.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

2018 327 citations Julius Strauss, Christopher R. Heery et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Italia Grenga United States	20	1.1k	617	337	326	157	43	1.6k
Carmen Oñate Spain	12	1.0k 0.9×	1.1k 1.7×	197 0.6×	354 1.1×	102 0.6×	19	1.7k
Kim C. Ohaegbulam United States	14	1.2k 1.1×	884 1.4×	339 1.0×	416 1.3×	143 0.9×	19	1.8k
Neeha Zaidi United States	20	994 0.9×	629 1.0×	261 0.8×	527 1.6×	181 1.2×	47	1.6k
Manabu Yasuda Japan	21	578 0.5×	471 0.8×	521 1.5×	397 1.2×	155 1.0×	91	1.4k
Ellen Moore United States	23	787 0.7×	796 1.3×	183 0.5×	334 1.0×	138 0.9×	48	1.6k
Julian A. Marin‐Acevedo United States	13	1.1k 1.0×	732 1.2×	358 1.1×	354 1.1×	81 0.5×	27	1.7k
Per Lindnér Sweden	23	661 0.6×	333 0.5×	170 0.5×	472 1.4×	308 2.0×	80	1.6k
Alex Chehrazi‐Raffle United States	11	869 0.8×	461 0.7×	331 1.0×	374 1.1×	138 0.9×	64	1.3k
Margaret E. Gatti‐Mays United States	16	746 0.7×	539 0.9×	170 0.5×	306 0.9×	72 0.5×	74	1.1k
Michail Doukas Netherlands	18	784 0.7×	363 0.6×	344 1.0×	279 0.9×	521 3.3×	108	1.6k

Countries citing papers authored by Italia Grenga

Since Specialization

Citations

This map shows the geographic impact of Italia Grenga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Italia Grenga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Italia Grenga more than expected).

Fields of papers citing papers by Italia Grenga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Italia Grenga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Italia Grenga. The network helps show where Italia Grenga may publish in the future.

Co-authorship network of co-authors of Italia Grenga

This figure shows the co-authorship network connecting the top 25 collaborators of Italia Grenga. A scholar is included among the top collaborators of Italia Grenga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Italia Grenga. Italia Grenga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Barlési, Fabrice, Sandrine Hiret, Christian Rolfo, et al.. (2020). Abstract CT267: A phase 1b/2, open-label study of bintrafusp alfa with chemotherapy in patients with stage IV non-small cell lung cancer. Cancer Research. 80(16_Supplement). CT267–CT267. 1 indexed citations

Vokes, Everett E., Alex A. Adjei, Myung‐Ju Ahn, et al.. (2019). P2.18-01 A Multicenter, Double-Blind, Randomized, Controlled Study of Bintrafusp Alfa (M7824) in Unresectable Stage III NSCLC. Journal of Thoracic Oncology. 14(10). S902–S902. 2 indexed citations

Strauss, Julius, Christopher R. Heery, Jeffrey Schlom, et al.. (2018). Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors. Clinical Cancer Research. 24(6). 1287–1295. 327 indexed citations breakdown →

Heery, Christopher R., Claudia Palena, Sheri McMahon, et al.. (2017). Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury. Clinical Cancer Research. 23(22). 6833–6845. 51 indexed citations

Rajan, Arun, Christopher R. Heery, Andrew L. Mammen, et al.. (2017). OA18.03 Safety and Clinical Activity of Avelumab (MSB0010718C; Anti-PD-L1) in Patients with Advanced Thymic Epithelial Tumors (TETs). Journal of Thoracic Oncology. 12(1). S314–S315. 12 indexed citations

Heery, Christopher R., Geraldine O’Sullivan Coyne, Ravi A. Madan, et al.. (2017). Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. The Lancet Oncology. 18(5). 587–598. 230 indexed citations

Donahue, Renee N., Lauren M. Lepone, Italia Grenga, et al.. (2017). Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody. Journal for ImmunoTherapy of Cancer. 5(1). 20–20. 61 indexed citations

Lepone, Lauren M., Renee N. Donahue, Italia Grenga, et al.. (2016). Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types. 5(1). 3 indexed citations

Farsaci, Benedetto, Renee N. Donahue, Italia Grenga, et al.. (2016). Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. Cancer Immunology Research. 4(9). 755–765. 26 indexed citations

10.

Rajan, Arun, Christopher R. Heery, Andrew L. Mammen, et al.. (2016). Safety and clinical activity of anti-programmed death-ligand 1 (PD-L1) antibody (ab) avelumab (MSB0010718C) in advanced thymic epithelial tumors (TETs).. Journal of Clinical Oncology. 34(15_suppl). e20106–e20106. 7 indexed citations

11.

Roselli, Mario, Vincenzo Formica, Vittore Cereda, et al.. (2016). The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy. OncoImmunology. 5(7). e1188243–e1188243. 25 indexed citations

12.

Heery, Christopher R., Myrna Rauckhorst, Jennifer L. Marté, et al.. (2015). Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury. Cancer Immunology Research. 3(11). 1248–1256. 104 indexed citations

13.

Grenga, Italia, Anna Kwilas, Renee N. Donahue, Benedetto Farsaci, & James W. Hodge. (2015). Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack. Journal for ImmunoTherapy of Cancer. 3(1). 52–52. 18 indexed citations

14.

Heery, Christopher R., Geraldine O’Sullivan Coyne, Jennifer L. Marté, et al.. (2015). Pharmacokinetic profile and receptor occupancy of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in a phase I, open-label, dose escalation trial in patients with advanced solid tumors.. Journal of Clinical Oncology. 33(15_suppl). 3055–3055. 19 indexed citations

15.

Farsaci, Benedetto, Renee N. Donahue, Italia Grenga, et al.. (2014). Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines. Cancer Immunology Research. 2(11). 1090–1102. 71 indexed citations

16.

Donahue, Renee N., Italia Grenga, Lauren M. Lepone, et al.. (2014). Identification of tumor associated immune responses against brachyury, a transcription factor and driver of EMT, in chordoma patients receiving a yeast-brachyury vaccine (gi-6301). Journal for ImmunoTherapy of Cancer. 2(S3). 3 indexed citations

17.

Formica, Vincenzo, Vittore Cereda, Italia Grenga, et al.. (2013). Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B). Medical Oncology. 30(4). 743–743. 19 indexed citations

18.

Grenga, Italia, Renee N. Donahue, James L. Gulley, et al.. (2013). Flow-cytometry phenotypic assessment of immune cell subsets reflecting function for the identification of breast cancer patients receiving vaccine plus docetaxel with longer progression-free survival. Journal for ImmunoTherapy of Cancer. 1(S1). 1 indexed citations

19.

Ferroni, Patrizia, Francesca Martini, Ilaria Portarena, et al.. (2012). Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients—a pilot study. Supportive Care in Cancer. 20(11). 2713–2720. 10 indexed citations

20.

Formica, Vincenzo, Raffaele Palmirotta, Girolamo Del Monte, et al.. (2010). Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab. International Journal of Colorectal Disease. 26(2). 143–151. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact